Meeting
2016 ASCO Annual Meeting
PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).
Authors
Joel Guigay
Centre Antoine-Lacassagne, Nice, France
Joel Guigay , Jerome Fayette , Caroline Even , Didier Cupissol , Frederic Rolland , Frederic Peyrade , Brigitte Laguerre , Christophe Le Tourneau , Sylvie Zanetta , Laurence Bozec Le Moal , Christian Borel , Pascal Do , Laurence Digue , Jessy Delaye , Anne Auperin , François Bidault , Valerie Costes , Laura Faivre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT02393820
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6086)
DOI
10.1200/JCO.2016.34.15_suppl.6086
Abstract #
6086
Poster Bd #
408
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
First Author: Youjin Kim
Poster
2023 ASCO Annual Meeting
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
First Author: Maliheh Mohamadpour
Poster
2022 ASCO Annual Meeting
A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies.
First Author: Katharine Andress Rowe Price
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel